Dayna Simpson
5 Papers
46 Citations
Dayna Simpson is an academic researcher. The author has contributed to research in topics: Rucaparib & Carboplatin. The author has an hindex of 5, co-authored 5 publications.
Chat about Author
Papers
A phase I study of oral rucaparib in combination with carboplatin.
L Rhoda Molife,Patricia Roxburgh,Richard H. Wilson,Avinash Gupta,Mark R. Middleton,T.R. Jeffry Evans,Caroline O. Michie,Joaquin Mateo,Donna Crawford,Martin Eatock,Wasir Saka,Nicola Cresti,Yvette Drew,Heidi Giordano,Darrin Despain,Dayna Simpson,Andrew R. Allen,Sarah Jaw-Tsai,Ruth Plummer +18 more
TL;DR: This study evaluated the tolerability of oral rucaparib, a potent and selective PARP1/2 inhibitor, in combination with carboplatin (CP) in patients aged ≥18 with advanced solid tumors.
18
Abstract A218: Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.
Geoffrey I. Shapiro,Rebecca Kristeleit,Mark R. Middleton,Howard A. Burris,L Rhoda Molife,Jeff Evans,Richard H. Wilson,Patricia LoRusso,James Spicer,Véronique Diéras,Manish R. Patel,E. Dominy,Dayna Simpson,Heidi Giordano,Andrew R. Allen,Sarah Jaw-Tsai,Ruth Plummer +16 more
TL;DR: Predictable PK following oral dosing may lead to low rates of over- and under- dosing, potentially minimizing AEs associated with high unpredictable exposures, an important attribute for maintenance therapy.
14
•Journal Article
Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.
Geoffrey I. Shapiro,Rebecca Kristeleit,Mark R. Middleton,Howard A. Burris,L. R. Molife,Jeff Evans,Richard H. Wilson,Patricia LoRusso,James Spicer,Véronique Diéras,Manish R. Patel,E. Dominy,Dayna Simpson,Heidi Giordano,Andrew R. Allen,Sarah Jaw-Tsai,Ruth Plummer +16 more
11
A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation.
Ronnie Shapira-Frommer,Amit M. Oza,Susan M. Domchek,Judith Balmaña,Manish R. Patel,Lee-may Chen,Yvette Drew,Howard A. Burris,Jacob Korach,Michael Flynn,Valerie Bowering,Mark A. Morgan,Simon Paul Watkins,Dayna Simpson,Sandra Goble,Lara Maloney,Rebecca Kristeleit +16 more
TL;DR: This phase II study evaluated the efficacy and safety of rucaparib in pts with relapsed gBRCAmut high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer and the primary endpoint was objective response rate (ORR) by RECIST 1.1.